APRE Logo

Aprea Therapeutics, Inc. (APRE) 

NASDAQ
Market Cap
$17.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
215 of 968
Rank in Industry
134 of 556

Largest Insider Buys in Sector

APRE Stock Price History Chart

APRE Stock Performance

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Insider Activity of Aprea Therapeutics, Inc.

Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $287,903 and sold $29,583 worth of Aprea Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $162,430 and sold $20.95M worth of stock each year.

Highest buying activity among insiders over the last 12 months: HENNEMAN JOHN B III (director) — $200,038. Seizinger Bernd R. (director) — $153,619. Duey Marc (director) — $132,190.

The last purchase of 500 shares for transaction amount of $1,958 was made by Gilad Oren (President/CEO) on 2024‑10‑23.

List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.

2024-10-23PurchasePresident/CEO
500
0.0086%
$3.92$1,9580.00%
2024-10-18Saledirector
6,462
0.1238%
$4.58$29,583-22.05%
2024-10-16Purchasedirector
30,000
0.8303%
$4.39$131,700+0.57%
2024-10-15PurchasePresident/CEO
250
0.0046%
$2.90$725+15.08%
2024-10-14PurchasePresident/CEO
1,000
0.0163%
$2.59$2,590+36.72%
2024-10-14Purchasedirector
190
0.0031%
$2.58$490+36.72%
2024-10-11Purchasedirector
10,000
0.169%
$2.68$26,800+33.27%
2024-10-11PurchaseSrVP/CFO/Prin Fin & Acct Ofcr
50
0.0008%
$2.46$123+33.27%
2024-10-10PurchasePresident/CEO
150
0.0024%
$2.54$381+35.04%
2024-10-10PurchaseSrVP/CFO/Prin Fin & Acct Ofcr
450
0.0074%
$2.61$1,175+35.04%
2024-03-13PurchasePresident, CEO
2,000
0.0683%
$7.29$14,580-26.67%
2024-03-13Purchasedirector
6,860
0.2342%
$7.29$50,009-26.67%
2024-03-13PurchaseSrVP/CFO/Prin Fin & Acct Ofcr
1,010
0.0345%
$7.29$7,363-26.67%
2024-03-13Purchasedirector
6,860
0.2342%
$7.29$50,009-26.67%
2023-06-07Purchasedirector
6,029
0.1917%
$3.68$22,192+21.41%
2023-06-06Purchasedirector
4,068
0.1208%
$3.63$14,764+13.87%
2020-12-28Sale10 percent owner
500,000
2.4014%
$5.58$2.79M-11.73%
2020-10-05SaleFormer 10% holder
175,000
0.7844%
$25.30$4.43M-80.91%
2020-07-07Sale10 percent owner
241,703
1.1593%
$34.55$8.35M-79.65%
2020-06-16SaleFormer 10% holder
120,164
0.5556%
$33.30$4M-38.45%

Insider Historical Profitability

48.45%
Gilad OrenPresident/CEO
333395
6.1343%
$3.1650
Duey Marcdirector
233651
4.2991%
$3.1621
Seizinger Bernd R.director
44730
0.823%
$3.1640+17.64%
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
19368
0.3564%
$3.1630
HENNEMAN JOHN B IIIdirector
8139
0.1498%
$3.1620+53.58%
Christenson Johandirector
2366104
43.5354%
$3.1610+53.58%
HealthCap VII, L.P.10 percent owner
2366104
43.5354%
$3.1610+53.58%
KDev Investments AB10 percent owner
1992586
36.6628%
$3.1602
Redmile Group, LLC10 percent owner
1768718
32.5437%
$3.1611+53.58%
Versant Vantage I, L.P.10 percent owner
333333
6.1332%
$3.1610+53.58%
Versant V Luxco S.a r.l.10 percent owner
333333
6.1332%
$3.1610+53.58%
5AM Ventures IV, L.P.Former 10% holder
138497
2.5483%
$3.1614+53.58%
ROCKLAGE SCOTT MFormer 10% holder
75965
1.3977%
$3.1603
Magni Guidodirector
6500
0.1196%
$3.1610+53.58%
SCHADE CHRISTIAN SPresident & CEO
5000
0.092%
$3.1610+53.58%
Coiante Scott MSVP, Chief Financial Officer
2500
0.046%
$3.1610+53.58%
Korbel Gregory AlanVP of Business Dev't
500
0.0092%
$3.1610+53.58%
Attar Eyal C.SVP, Chief Medical Officer
200
0.0037%
$3.1610+53.58%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.